International Symposium on Compound Design Technologies: Guiding Better Decisions in Drug Discovery and Development

Cambridge, UK – 6th February 2014 – Cresset, Optibrium, Lhasa Limited and Chemogenomix, innovative providers of computational chemistry software and services, announce the ‘International Symposium on Compound Design Technologies’. The symposium will be held on March 19th at the British Embassy in Tokyo and on March 20th at the British Consulate-General in Osaka.

Of particular interest to computational chemists working in the pharmaceutical, biotechnology and drug discovery industries, attendees will hear about technologies that guide them to successful small molecule and biotherapeutic drug discovery and development, intuitive molecular design and 3D-QSAR interpretation as well as knowledge based toxicity prediction.

The keynote presentation will be made by Dr John Overington (EMBL-EBI) with other presentations from Dr. Kimito Funatsu (University of Tokyo), Dr. Yoshio Hamada (Kobe Gakuin University) and Dr. Hiroshi Chuman (University of Tokushima), Dr. Matt Segall (Optibrium), Dr. Tim Cheeseright (Cresset), Dr. Thierry Hanser (Lhasa Limited) and Dr. Mark Swindells (Chemogenomix).

The full program, and free registration, is online at http://www.cresset-group.com/news-events/events/international-symposium-on-compound-design-technologies/.